Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
Abstract Imiquimod (IMQ), a drug from aminoquinoline group, is the toll-like receptor 7 (TLR7) agonist. It acts as an immunostimulant and radio-sensitizing agent. IMQ stimulates both innate and adaptive immune response. Despite studies conducted, there are no unambiguous data showing how IMQ affects...
Saved in:
| Main Authors: | Jarosz-Biej Magdalena, Czapla Justyna, Ciepła Joanna, Smolarczyk Ryszard, Drzyzga Alina, Sprus-Lipka Dorota, Pilny Ewelina, Matuszczak Sybilla, Cichoń Tomasz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-02-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-03943-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
by: Magdalena Jarosz-Biej, et al.
Published: (2025-05-01) -
Ivermectin decreases inflammation and imiquimod–induced psoriasis-like skin lesions in rat via targeting TLR4 / p65 NF-κB
by: Tayebeh Noori, et al.
Published: (2025-06-01) -
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
by: Aashna Jassal, et al.
Published: (2024-11-01) -
Imiquimod liposome gel preparations and their ability to inhibit hypertrophic scars
by: Yujian LIN, et al.
Published: (2021-06-01) -
Cladribine Ameliorates Imiquimod Induced Murine Psoriasiform Dermatitis
by: Xue J, et al.
Published: (2025-02-01)